TriPath's Ki-67 with Ventana imager:
This article was originally published in Clinica
TriPath Imaging has received US FDA 510(k) market clearance to use a Ventana-branded version of its interactive histology image analysis system with tissues stained for Ki-67, a cell proliferation biomarker for helping with the diagnosis and prognostic assessment of cancer. "This is the first time the Ki-67 marker has been cleared by the FDA for use with an image analysis system," said Paul Sohmer, TriPath's chairman, president and CEO. The Ventana image analysis system received US clearance last year for use with oestrogen receptor, progesterone receptor and HER-2/neu assays. In 2004, TriPath, of Burlington, North Carolina, gave Tucson, Arizona-based Ventana exclusive rights to sell and distribute worldwide a Ventana-branded version of its imaging system, optimised for both Ventana and TriPath assays.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.